Jenphar Bangladesh Limited is pleased to announce the successful launch of new oncology product Pazopanib Hydrochloride 400 mg tablet as the brand name of Zotrix 400 tablet.
![](http://jenphar.com/wp-content/uploads/2023/06/WhatsApp-Image-2023-06-25-at-5.27.10-PM-1024x783.jpeg)
Pazopanib Hydrochloride is an oral, potent, multi-targeted tyrosine kinase inhibitor. By Inhibiting the VEGFR-1, -2 & -3, PDGFR-α & -β, and c-Kit, it inhibits angiogenesis, tumor growth and proliferation.
By launching this product, Jenphar Bangladesh Limited has enriched its Oncology portfolio, offering the treatment options in Advanced Renal Cell Carcinoma & Advanced Soft Tissue Sarcoma which will serve in a better way to the mentioned cancer patients of the country & abroad.
Zotrix 400 mg Tab is available in a sealed HDPE container containing 14 Tablets.